VEGFR-2 inhibitor
VEGFR-2 inhibitor refers to a class of therapeutic agents that target and inhibit the activity of the Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). VEGFR-2 is a key tyrosine kinase receptor involved in the regulation of angiogenesis, the process by which new blood vessels form from pre-existing vessels. This process is critical in the growth and spread of cancer, making VEGFR-2 an important target in cancer therapy.
Mechanism of Action[edit | edit source]
VEGFR-2 inhibitors work by blocking the binding of vascular endothelial growth factor (VEGF) to its receptor, VEGFR-2. This inhibition prevents the activation of the receptor and its downstream signaling pathways that are involved in the promotion of angiogenesis. By inhibiting these pathways, VEGFR-2 inhibitors can reduce the supply of nutrients and oxygen to tumors, thereby inhibiting their growth and potential to spread.
Clinical Applications[edit | edit source]
VEGFR-2 inhibitors are used in the treatment of various types of cancers, including renal cell carcinoma, hepatocellular carcinoma, and certain types of lung cancer. They are also being investigated for their potential in treating other conditions characterized by excessive angiogenesis, such as age-related macular degeneration.
Examples of VEGFR-2 Inhibitors[edit | edit source]
Some examples of VEGFR-2 inhibitors include:
These drugs vary in their specificity for VEGFR-2 and may also inhibit other related receptors, which can influence their efficacy and side effect profiles.
Side Effects[edit | edit source]
The inhibition of VEGFR-2 can lead to a range of side effects, as angiogenesis is a normal process in the body for healing and growth. Common side effects of VEGFR-2 inhibitors include hypertension, fatigue, diarrhea, and hand-foot syndrome. More serious side effects can include heart problems, hemorrhage, and thromboembolism.
Future Directions[edit | edit source]
Research is ongoing to develop more selective and potent VEGFR-2 inhibitors, with the aim of improving efficacy and reducing side effects. Additionally, studies are exploring the combination of VEGFR-2 inhibitors with other therapeutic agents to enhance cancer treatment outcomes.
 | This oncology article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
